RxDoctor Payments Data

Jose Alvarez, MD

General Practice · Miami, FLNPI 1205873817

Payments from drug & device makers

$314,601in general payments, 2019–2025

Across 93 payments — averaging $3382.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$166K
  • Sanofi US Services Inc.$43K
  • AstraZeneca$43K
  • Lexicon Pharmaceuticals, Inc.$20K
  • Novo Nordisk AS$18K
  • Chiesi USA, Inc.$10K
  • plus $14K from 11 others

What the payments were for

  • Speaking & faculty fees$6,60087%
  • Food & beverage$1,01813%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$314,601 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$292,814
Medicare patients
13
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$56,162
OzempicSemaglutide25$24,361
XareltoRivaroxaban16$20,065
JanuviaSitagliptin Phosphate30$17,645
MounjaroTirzepatide14$16,175
FarxigaDapagliflozin Propanediol20$11,822
Albuterol Sulfate HfaAlbuterol Sulfate327$9,424
TradjentaLinagliptin18$9,063
SymbicortBudesonide/Formoterol Fumarate36$8,183
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$6,344
Rosuvastatin Calcium615$3,554
Insulin Aspart FlexpenInsulin Aspart11$2,628
Levothyroxine Sodium378$2,454
Dabigatran EtexilateDabigatran Etexilate Mesylate14$2,098
Oxybutynin Chloride ErOxybutynin Chloride115$1,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$43,149$20,00556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →